<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691063</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1316-III-302</org_study_id>
    <nct_id>NCT04691063</nct_id>
  </id_info>
  <brief_title>The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.</brief_title>
  <official_title>A Multi-center, Randomized, Double-blinded, Phase III Trial of SHR-1316 or Placebo in Combination With Chemo-radiotherapy in Patients With Limited-stage Small-cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination&#xD;
      with chemo-radiotherapy in patients with LS-SCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1316 in combination with chemo-radiotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316; Carboplatin; Etoposide；Radiotherapy</intervention_name>
    <description>SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palcebo; Carboplatin; Etoposide；Radiotherapy</intervention_name>
    <description>Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18-75 years of age.&#xD;
&#xD;
          2. Subjects with histologically confirmed Limited-Stage SCLC without previous systematic&#xD;
             treatment.&#xD;
&#xD;
          3. ECOG PS 0~1.&#xD;
&#xD;
          4. At least 1 measurable lesion as defined by RECIST v1.1.&#xD;
&#xD;
          5. Adequate organ function.&#xD;
&#xD;
          6. Female subjects of childbearing potential or male subjects must be willing to use a&#xD;
             recognized effective contraceptive measure during the study and within 3 months after&#xD;
             the last dose of the study drug. And female subjects of childbearing potential must&#xD;
             have a negative serum pregnancy test within 7 days prior to the first dose.&#xD;
&#xD;
          7. Signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mixed SCLC or NSCLC.&#xD;
&#xD;
          2. Subjects who previously received systemic antitumor or Immune checkpoint inhibitor&#xD;
             therapy.&#xD;
&#xD;
          3. Extensive-stage SCLC.&#xD;
&#xD;
          4. Subjects who is surgically resectable.&#xD;
&#xD;
          5. Subjects with malignant pleural effusion.&#xD;
&#xD;
          6. Subjects highly suspected of interstitial lung disease, or with conditions that may&#xD;
             interfere with the testing or management of suspected treatment-related pulmonary&#xD;
             toxicities, or other moderate to severe diseases that seriously affect pulmonary&#xD;
             function.&#xD;
&#xD;
          7. Active, known, or suspected autoimmune diseases.&#xD;
&#xD;
          8. History of malignant tumors.&#xD;
&#xD;
          9. Subjects with severe cardiovascular disease.&#xD;
&#xD;
         10. Events of arterial/venous thrombosis within 6 months prior to the first dose.&#xD;
&#xD;
         11. Subjects with serious infection.&#xD;
&#xD;
         12. Subjects with active pulmonary tuberculosis (TB).&#xD;
&#xD;
         13. Subjects with immunodeficiency diseases.&#xD;
&#xD;
         14. Subjects with active hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
         15. Systemic immunosuppressants administation within 14 days prior to the first dose.&#xD;
&#xD;
         16. Subjects who received major surgery within 28 days prior to the first dose.&#xD;
&#xD;
         17. Subjects who plan to receive or have received live vaccines within 28 days prior to&#xD;
             the first dose.&#xD;
&#xD;
         18. Subjects who have previously received tissue/organ transplants.&#xD;
&#xD;
         19. Subjects with history of severe allergic reactions to monoclonal antibodies/fusion&#xD;
             protein drugs.&#xD;
&#xD;
         20. Subjects with mental illness, alcohol abuse, inability to quit smoking, and drug or&#xD;
             substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

